{
    "clinical_study": {
        "@rank": "80544", 
        "arm_group": {
            "arm_group_label": "Gefitinib"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to understand real world gefitinib usage patterns, patient\n      characteristics and outcomes and to  present these for a Caucasian population"
        }, 
        "brief_title": "Gefitinib Usage and Outcomes in Routine Treatment", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Lung Cancer", 
        "condition_browse": {
            "mesh_term": "Lung Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "A multicentre, retrospective chart review study to characterise gefitinib usage and outcomes\n      in routine treatment"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who received gefitinib first line in the UK Single Payment Access (SPA)\n             scheme\n\n          -  Locally advanced or metastatic EGFR mutation positive NSCLC\n\n          -  Supplied with first pack of gefitinib prior to 1st January 2012\n\n        Exclusion Criteria:\n\n          -  Patient was treated privately (i.e. outside the NHS)\n\n          -  Gefitinib was second-line therapy following treatment failure on a prior therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "hospital clinic"
            }
        }, 
        "enrollment": {
            "#text": "157", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01818947", 
            "org_study_id": "NIS-OGB-IRE-2012/1"
        }, 
        "intervention_browse": {
            "mesh_term": "Gefitinib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lung cancer", 
            "epidermal growth factor receptor mutation", 
            "gefitinib", 
            "Iressa"
        ], 
        "lastchanged_date": "January 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Queen Elizabeth Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cardiff", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Velindre Nhs Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harrogate", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Harrogate District Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Leeds Teaching Hospitals"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liverpool", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Liverpool Heart and Chest Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Mount Vernon Hospital Nhs Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Royal Marsden Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "University College Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Christie Hospital Nhs Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nottingham", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Nottingham University Hospitals Nhs Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sheffield", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Northern General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "York", 
                        "country": "United Kingdom"
                    }, 
                    "name": "York District Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multicentre, Retrospective Chart Review Study to Characterise Gefitinib Usage and Outcomes in Routine Treatment", 
        "overall_official": {
            "affiliation": "The Christie NHS Foundation Trust", 
            "last_name": "Fiona Blackhall, MBCHB FRCP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kindom: Not Applicable for Observational and Retrospective Study", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Retrospective population [2009 to 2013]", 
                "measure": "Assessment of treatment duration, as a surrogate of Clinical Benefit (CB) in a 'Real World' population treated with gefitinib", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Retrospective population [2009 to 2013]", 
                "measure": "Assessment of Overall Survival (OS) in a 'Real World' population treated with gefitinib", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01818947"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Retrospective population [2009 to 2013]", 
                "measure": "Assessment of Overall Survival (OS) in the subgroup of patients of Caucasian ethnicity and in the subgroup of patients treated with gefitinib for at least 3 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Retrospective population [2009 to 2013]", 
                "measure": "Assessment of Treatment duration in the subgroup of patients of Caucasian ethnicity and in the subgroup of patients treated with gefitinib for at least 3 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Retrospective population [2009 to 2013]", 
                "measure": "Characteristics of patients treated with gefitinib for all patients and stratified by whether gefitinib discontinued treatment before or after three months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Retrospective population [2009 to 2013]", 
                "measure": "Description of treatment patterns in patients treated with gefitinib (prior chemo, treatment breaks, treatment on discontinuation)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Retrospective population [2009 to 2013]", 
                "measure": "Duration of treatment in patients stratified by age, gender, stage and performance status.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Retrospective population [2009 to 2013]", 
                "measure": "Overall Survival (OS) in patients stratified by age, gender, stage and performance status.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}